The objective measurement of remission and progression in metastatic breast cancer by use of serum tumor markers

European Journal of Cancer

Volumn 35, Issue 1, 1999, Pages 47-53

  Robertson, J F R ^a   Jaeger, W ^b   Syzmendera, J J ^c   Selby, C ^a   Coleman, R ^d   Howell, A ^e   Winstanley, J ^f   Jonssen, P E ^g   Bombardieri, E ^h   Sainsbury, J R C ⁱ   Gronberg, H ^j   Kumpulainen, E ^k   Blamey, R W ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d WESTON PARK HOSPITAL   (United Kingdom)

^e CHRISTIE HOSPITAL   (United Kingdom)

^f ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^g HELSINGBORG HOSPITAL   (Sweden)

^h National Tumour Institute   (Italy)

ⁱ HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

^j UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^k KUOPIO UNIVERSITY HOSPITAL   (Finland)

more..

Author keywords

Breast cancer; Metastatic; Monitoring therapy; Tumor markers

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CARBOHYDRATE ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; FLUOROURACIL; GONADORELIN DERIVATIVE; GOSERELIN; MEGESTROL ACETATE; METHOTREXATE; ONAPRISTONE; PACLITAXEL; TAMOXIFEN; TUMOR MARKER;

ANTIGEN DETECTION; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER REGRESSION; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BLOOD SEDIMENTATION; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; REMISSION INDUCTION;

EID: 0032991137     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00297-4     Document Type: Article

References (23)

1. Mughal A.W., Hortobagyi G.N., Fritsche H.A., et al. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 249:1983;1881-1886.
2. Lee Y.N. Serial test of carcinoembryonic antigen in patients with breast cancer. Am J Clin Oncol (CCT). 6:1983;287-293.
3. Hayes D.F., Zurawski V.R., Kufe D.W. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 10:1986;1542-1550.
4. Todini C., Hayes D.F., Gelman R., et al. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Can Res. 48:1988;4107-4112.
5. Martoni A., Zamagni C., Bellanova B., et al. CEA, MCA, CA15-3 and CA549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur J Cancer. 31A:1995;1615-1621.
6. Van Dalen A., Van Der Linde D.L., Heering K.J., et al. How can treatment response be measured in breast cancer patients. Anticancer Research. 13:1993;901-1904.
7. Van Dalen A., Heering K.J., Barak V., et al. Treatment response in metastatic breast cancer. A multicentre study comparing UICC criteria and tumour marker changes. The Breast. 5:1996;82-88.
8. Williams M.R., Turkes A., Pearson D., et al. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer. 61:1990;126.
9. Robertson J.F.R., Pearson D., Price M.R., et al. Objective measurement of therapeutic response in breast cancer using serum markers. Br J Cancer. 64:1991;757-763.
10. Dixon AR, Jackson L, Chan SY, et-al. Serological monitoring of advanced breast cancer treated by systemic cytotoxics by a combination of CEA, CA15-3, and ESR: fact or fiction? Disease Markers 1991, 9(3-4), 167-174.
11. Dixon AR. Tumour markers - a logical approach to the guidance of therapy in advanced breast cancer? MD Thesis, Nottingham University, May 1992.
12. Dixon A.R., Jackson L., Chan S.Y., et al. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer. 68:1993;181-185.
13. Hayward J.L., Carbonne P.P.K., Heuson J.C., et al. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 39:1979;1289-1294.
14. Robertson J.F.R., Williams M.R., Todd J., et al. Factors predicting the response of patients with advanced breast cancer to endocrine (megace) therapy. Eur J Cancer Clin Oncol. 25:1989;469-475.
15. Howell A., Mackintosh J., Jones M., et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemo-therapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol. 24:1988;1567-1572.
16. Robertson JFR, Willsher PC, Cheung KL, et al. The clinical relevance of static disease (no change) category for 6 months one endocrine therapy in patients with breast cancer. Eur J Cancer, 1997, 33, 1774-1779.
17. Kiang D.T., Greenberg L.J., Kennedy B.J. Tumour marker kinetics in the monitoring of breast cancer. Cancer. 65:1990;193-199.
18. Willsher P., Beaver J., Blarney R.W., et al. Tissue polypeptide specific antigen (TPS) in the serum of patients with breast cancer. Anticancer Res. 15:1995;1609-1612.
19. Barak V., Nisman B., Roisman I., et al. TPS in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J Tumor Marker Oncol. 12:1997;17-25.
20. Ng J.S.Y., Sturgeon C., Seth J., et al. Serological markers for metastatic breast cancer. Dis Markers. 11:1993;217-223.
21. Schuurman J.J., Bong S.B., Einarsson R. Determination of serum tumor markers TPS and CA15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res. 16:1996;2169-2172.
22. Giai M., Roagna R., Ponzone R., et al. TPS and CA15-3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res. 16:1996;875-882.
23. Robertson J.F.R., Whynes D.K., Dixon A.R., et al. Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer. 72:1995;174-177.